The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 02, 2021

Filed:

Feb. 01, 2016
Applicants:

Novartis Ag, Basel, CH;

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Inventors:

Carl H. June, Merion Station, PA (US);

Daniel J. Powell, Jr., Bala Cynwyd, PA (US);

Assignees:

Novartis AG, Basel, CH;

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/32 (2006.01); C07K 14/725 (2006.01); A61K 39/395 (2006.01); A61K 35/17 (2015.01); C07K 14/705 (2006.01); C07K 16/30 (2006.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C12N 15/113 (2010.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61K 35/17 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 14/54 (2013.01); C07K 14/5418 (2013.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C12N 15/113 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/22 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01);
Abstract

The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.


Find Patent Forward Citations

Loading…